Skip to main contentWhat is HPLC purity testing?
High-Performance Liquid Chromatography — HPLC — is the analytical method that quantifies how much of a sample is the target compound versus everything else present. In the context of synthetic research peptides, "everything else" includes truncated deletion sequences from incomplete synthesis steps, oxidation products on susceptible residues, residual protecting groups from solid-phase chemistry, solvent adducts, and aggregated multimers that form after lyophilization. None of these impurities are visible to the eye. The lyophilized powder in a vial looks the same whether it contains 94% target peptide or 99.6% — HPLC is the instrument that draws that distinction.
The technique works by forcing a dissolved sample through a column packed with stationary-phase material under high pressure, using a flowing liquid mobile phase to carry compounds through. Compounds interact with the stationary phase to varying degrees based on their chemical properties, and those differences in interaction translate into different transit times through the column. A detector at the column exit records a signal as each compound passes through, producing a time-resolved profile of what was in the sample. That profile — the chromatogram — is the primary output, and purity is calculated directly from it.
For research sourcing decisions, HPLC purity data is the single most information-dense number on a Certificate of Analysis. Understanding how that number is generated is what separates informed procurement from accepting a figure on faith.
How does reverse-phase HPLC separate peptides?
The HPLC configuration used for peptide analysis is reverse-phase, abbreviated RP-HPLC. The stationary phase is a silica support bonded with long hydrocarbon chains — typically C18, meaning 18-carbon alkyl groups. The mobile phase is an aqueous-organic solvent system, usually water and acetonitrile, with a small percentage of trifluoroacetic acid added to control ionization and improve peak shape.
In this setup, the relationship between peptide and column is driven by hydrophobicity. Peptides with a higher proportion of nonpolar residues — tryptophan, phenylalanine, leucine, isoleucine, valine — interact more strongly with the C18 surface and take longer to elute. Peptides with predominantly polar or charged residues spend more time in the mobile phase and elute earlier. The organic solvent content of the mobile phase is increased gradually over the run — a gradient — which pulls compounds off the stationary phase progressively from most hydrophilic to most hydrophobic.
This gradient approach is essential for peptides because a typical synthetic batch contains impurities that span a wide range of hydrophobicity. A truncated sequence missing one hydrophobic residue will elute slightly earlier than the full-length target. An oxidized methionine product will shift earlier than the native sequence because oxidation reduces hydrophobicity. An aggregate or dimer will often elute later. The gradient resolves all of these into distinct peaks that the detector can register individually.
UV detection at 214 nm is standard for peptides. At that wavelength, absorbance is dominated by the peptide bond itself, so signal response is proportional to the number of peptide bonds in the molecule rather than the presence of a specific chromophore. This makes 214 nm detection broadly applicable across different peptide sequences without requiring compound-specific calibration for each analysis.
How is area-percent purity calculated?
The chromatogram output is a plot of detector response over time. Integration software processes this by fitting boundaries around each distinguishable peak and calculating the area enclosed. The purity calculation is then straightforward:
Purity (%) = (Target peptide peak area ÷ Total integrated peak area) × 100
This is called the area-percent method. It is a relative measure — the target compound's contribution to total UV absorbance at 214 nm, expressed as a percentage of the sum of all detected contributions. Research-grade peptides are typically characterized at ≥98% or ≥99% area-percent purity depending on application requirements, with ≥99% being the standard threshold for well-characterized research compounds.
The area-percent method has a specific assumption embedded in it: that all compounds in the sample absorb comparably at 214 nm per unit mass. This holds reasonably well for peptides because absorbance at 214 nm is dominated by backbone peptide bonds, and impurities in a synthetic peptide batch are usually closely related structures (truncation products, modifications) that absorb similarly. It is a less reliable assumption when impurities are chemically dissimilar, such as residual organic solvents or small-molecule reagent contaminants, which is one reason HPLC purity assessment for peptides is specifically most reliable when the sample has been adequately purified upstream.
The percentage itself is only as meaningful as the integration underlying it. Integration parameters — where peak boundaries are set, how baseline is drawn, whether partially resolved shoulders are treated as separate peaks or folded into the main peak — all affect the calculated area. This is why access to the raw chromatogram matters. A purity percentage reported without a supporting chromatogram image is a number without an audit trail.
What does a COA report from HPLC analysis?
A Certificate of Analysis documents the HPLC analytical result in a standardized format. The purity value appears as a percentage with an associated specification, typically "≥98.0%" or "≥99.0%", alongside the actual measured result for that batch. Analytical parameters recorded alongside the result include the method reference, column specifications, mobile phase composition, gradient profile, detection wavelength, and sample preparation details. These parameters collectively define the analytical conditions that produced the reported result.
Batch-specific information connects the result to a production lot: batch number, analysis date, analyst identification, and instrument identification. This traceability chain allows the result to be linked back to the specific analytical run if questions arise. Published quality frameworks for analytical documentation establish that a purity result is only meaningful when it can be traced to a specific, documented analytical event — not a generic template applied across batches.
The chromatogram image, when included, shows the actual peak profile: the dominant target peptide peak and any minor peaks representing detected impurities. Retention times for each identified peak appear either on the chromatogram or in an accompanying table. For sourcing evaluation, the chromatogram provides qualitative information beyond the single percentage: the number of visible impurity peaks, their relative sizes and positions, and whether the main peak shows the symmetric shape expected of a well-resolved pure compound or shows tailing and fronting that indicate co-eluting species.
Suppliers operating functional quality systems generate batch-specific chromatograms — different trace profiles for different batches, reflecting actual analytical runs rather than file reuse. Identical chromatograms across multiple batch numbers from a supplier is a documentation integrity flag.
Why does purity matter for research compound sourcing?
At the batch level, purity is a direct measure of what is entering a research protocol. At 99% area-percent purity, a 1 mg sample of research peptide contains approximately 10 micrograms of uncharacterized material. Whether that 10 micrograms is inert or biologically active in the experimental system is unknown without specific characterization of the impurity profile.
For receptor binding studies, enzyme inhibition assays, or cell culture work at nanomolar concentrations, impurities present at even sub-percent levels can contribute confounding signal if they bind to the same targets as the intended compound. Truncated sequences from the same synthesis as a receptor-binding peptide often retain partial binding activity because they share the same pharmacophore region. Oxidation products at specific residues may have altered activity profiles relative to the native sequence. The 1% that is not the target compound is not necessarily inert.
Reproducibility across batches is the second reason purity specification matters in sourcing. Two batches both reporting 98% purity may have substantially different impurity compositions — the first percent of impurity is not consistent across synthesis runs. For longitudinal research protocols running experiments across multiple orders, tighter purity thresholds reduce this source of batch-to-batch variability in the experimental material entering the assay.
From a sourcing perspective, the supplier's ability to consistently deliver at a stated purity threshold across multiple batches is a more meaningful quality signal than any single analytical result. A supplier with documented batch-over-batch HPLC data showing consistent results across different production lots has demonstrated process control. A supplier providing a single COA without accessible batch history has demonstrated that one batch was tested — a much weaker basis for procurement decisions.
What distinguishes validated HPLC methods from unvalidated ones?
Method validation establishes that an analytical procedure is fit for its intended purpose — that it consistently measures what it claims to measure with defined accuracy and reproducibility. For HPLC purity testing of research peptides, validated methods include documented performance characteristics: specificity (the method measures the target without interference from known impurities), linearity (detector response is proportional to concentration across the working range), precision (repeated measurements of the same sample give consistent results), and system suitability (the instrument performance is confirmed before each analytical run using reference standards with defined acceptance criteria).
System suitability is the day-of-run check. Before analyzing a batch, the analyst injects a reference standard and confirms that key parameters — peak resolution, tailing factor, theoretical plate count — meet predefined criteria. This step catches instrument drift, column degradation, and mobile phase preparation errors before they affect sample results. Published guidance from analytical chemistry bodies establishes system suitability testing as a required element of validated HPLC methods, not an optional quality addition.
For research compound procurement, the distinction between validated and unvalidated HPLC methods has sourcing implications. Third-party testing laboratories operating under established quality management systems apply validated methods with documented system suitability. Internal testing at manufacturing sites with inadequate quality oversight may use HPLC instrumentation without the validation and system suitability infrastructure that makes results defensible. COAs referencing specific, auditable test methods — including column type, gradient, detection parameters, and method validation status — represent a higher confidence tier than those reporting a purity percentage with no methodological detail.
How does HPLC fit into a complete analytical package?
HPLC purity testing is the primary quantification method for peptide characterization, but it does not stand alone in a complete analytical package. Mass spectrometry provides molecular identity confirmation that HPLC cannot — a purity value tells you what fraction of the sample is the dominant compound but not whether that compound's molecular weight matches the target sequence. A sample can show 99% purity by HPLC while the dominant peak represents a synthesis error rather than the intended peptide, a scenario mass spectrometry would immediately flag.
Endotoxin testing by Limulus Amebocyte Lysate assay addresses a class of contamination invisible to HPLC — lipopolysaccharide from gram-negative bacterial contamination introduced during synthesis or lyophilization. Endotoxin is biologically active at very low concentrations in cell-based assays and is the primary contamination concern for research peptides used in in vitro cellular work. Published analytical frameworks for research-grade biological compounds list endotoxin testing alongside HPLC and mass spectrometry as the three core analytical requirements, not as optional supplementary testing.
The sourcing implication is straightforward: a COA reporting only HPLC purity is a partial document. A COA reporting HPLC purity, mass spectrometry identity confirmation, and endotoxin levels — with methods and results for each — represents the minimum complete analytical characterization package for research-grade peptide compounds. Sourcing decisions based on HPLC purity alone without identity confirmation and endotoxin data are working with an incomplete picture of the material entering the research protocol.
Research Use Only: All compounds available through Onward Aminos are intended exclusively for in vitro laboratory research by qualified researchers. Not for human or animal administration, consumption, or therapeutic use. These products are not drugs, supplements, or food products. Statements on this site have not been evaluated by the Food and Drug Administration. Must be 21 or older to purchase.